Sunday, September 14 at 2pm
SoulCycle, 266 Mason Street
2:45 Conversation with breast cancer survivor and GA graduate, Tomomi Arikawa
Teens and Adults welcome - SPACE IS LIMITED TO THE FIRST 60 RSVPs
Register now at: http://weblink.donorperfect.com/SoulCycleforBCARead More
Enjoy a day in Greenwich
dedicated to Breast Cancer Awareness Month
Thursday, October 2
Mention Go For Pink and a donation will be made to Breast Cancer Alliance at participating merchants*
Attend Go For Pink ~ sip, shop and support as a community throughout the day
Support Go For Pink ~ shopping receptions from 5-8PM and at Richards of Greenwich from 5-9PM
Breast Cancer Alliance flag raising at Town Hall at 9AM ~ First Selectman Peter Tesei plans to attend
Participating Merchants to date include:
Alease Fisher Designs, Alice and Olivia, Amina Rubinacci, Anne Fontaine, Carlisle, Christina Addison, CLAY Health Club & Spa, Comptoir des Cotonniers, The Shop@Equinox, French Sole, Gabby, Hoagland’s of Greenwich, Intermix, J. Crew, J. Papers, Kate Spade, Lilly Pulitzer, Lynnens Inc., McArdle’s Florist and Garden Center, Michael Kors, OGGI 5, Plush Blow, R. Simantov Fine Jewelry, Richards of Greenwich, Roam, Shoes N More, Simon Pearce, Splurge, Steven Fox Jewelry, Stuart Weitzman, Sweaty Betty, Tangerine, Theory, Tory Burch, Vilebrequin, Vince, Vineyard Vines, Warren Tricomi Salon and Winston Flowers.
*The list of merchants will be updated as the event nears
**If you are a merchant and would like to get involved, please click on the links below to download additional information:
We look forward to seeing you on November 6!
To purchase patron-level tickets now, please contact firstname.lastname@example.org or call the BCA office, 203.861.0014. Event invitations will be in the mail soon.
To begin bidding on our fabulous silent auction, go to:
Click here to read the latest issue of our newsletter, Outlook, online! If you prefer to receive a hard copy, please contact the office to be sure you are on our mailing list at email@example.com.Read More
Each year, in accordance with our commitment to due diligence, we visit each of the institutions to whom we provide a grant allocation.
The remaining dates for this year’s visits are listed below. If you would like to attend one of these visits, or receive more information about timing and content, please contact Crystal Stoute, Executive Assistant, at firstname.lastname@example.org.
September 9: Gilda’s Club
September 16: Norma F. Pfriem Breast Care Center, St. Vincent’s Hospital and The Witness Project
Thomas Jefferson University, Hallgeir Rui: Dr. Rui has developed a mouse model, expressing human prolactin hormone, that is duplicative of the human system with breast cancer. This model is being used to test the efficacy of prolactin suppression alone or in combination with anti-estrogens on lung metastases after removal of a primary tumor.
Columbia University, Jose M. Silva: This study aims to analyze the genetic fingerprint of inflammatory breast cancer, and identify those alterations that are associated with tumorigenicity, with an eye to identifying new targets for treatment.
Weill Medical College of Cornell University, Lewis (Lew) S. Cantley (with Gerburg M. Wulf on skype): Dr. Cantley and Dr. Wulf are using mouse models to determine which combinations of PI3K (a known cancer promoter) inhibitors and other chemotherapeutic agents have a beneficial effect on cancers that do not respond to estrogen receptor blockers or Her-2 blocking agents.
October 14: Stamford Hospital
Dana-Farber Cancer Institute
Constantine S. Mitsiades: Dr. Mitsiades has previously observed that “accessory” non-metastatic cells aid metastatic cells in their resistance to chemotherapy. The present study is examining the mechanisms by which these accessory cells may work in aiding estrogen-receptor mutated tumor cells in becoming resistant to anti-estrogen therapies, in the context of bone metastases, the most common, but infrequently studied, of breast cancer metastatic sites.
Kornelia (Nelly) Polyak: Based on prior observations of metabolic differences between tumor cells and normal cells, Dr. Polyak’s study is looking at the role that metabolic changes induced by stromal (normal) cells play in the development of tumor cells’ therapeutic resistance, with an aim to identify possible metabolic pathways as therapeutic targets.Read More